Epithelioid Angiosarcoma of Esophagus
Xu Wei,Zhan Na,Dong Wei-guo,Xiong Cheng-long
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20130308
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:Epithelioid angiosarcomas (EAS) are very uncommon tumors accounting for less than 1% of all sarcoma and most frequently occur in the skin and subcuits. Primary angiosarcomas in alimentary tract are very rare, especially in esophagus and only one case has been reported in the Chinese literature.1 Evidence-based advice regarding optimal management is lacking. Here, we reported a case of 54-year-old man who was found to have EAS in the esophagus. A 54-year-old Chinese man who had presented with progressively increasing dysphagia and weight loss was admitted to Renmin Hospital of Wuhan University. He had no family history of esophageal cancers, and he as well as his family had no past history of cancers, but he revealed chronic alcoholism and heavy smoking. Routine laboratory studies had no abnormalities. An upper gastrointestinal barium study revealed a polypoid intraluminal filling defect of 9.0 cm in the distal esophagus (Figure 1A). An endoscopic examination showed a tan-redish-coated polypoid tumor, which floated in the esophagus by a narrow stalk of tumor located at 3.2 cm from the incisor teeth (Figure 1B). A computed tomography scan showed remarkable intraluminal tumor in the esophagus. A subtotal esophagotomy was carried out.Figure 1.: An upper gastrointestinal barium study revealed a polypoid intraluminal filling defect of 9.0 cm in the distal esophagus (A). An endoscopic examination showed a tan-redish-coated polypoid tumor (B). A large polypoid tumor was attached to the esophageal wall by a narrow stalk (C). A malignant tumor made up of haphazardly arranged cell fascicles diffusely infiltrating the superficial muscle layer (HE, original magnification ×100) (D). Tumor cells with distinct epithelioid appearance line irregular anastomosing vascular channels containing red blood cell. All tumor cells have vesicular nuclei with peripheral chromatincondensation and prominent nucleoli (HE, original magnification ×200) (E). The neoplastic cells were strongly positive for CD31 (ABC, original magnification ×200) (F).Macroscopically, a large polypoid tumor, measuring 9.0 cm × 2.5 cm × 2.5 cm, was attached to the esophageal wall by a narrow stalk (Figure 1C). The neoplasm surface was erosive and necrotic, and its cut surface was solid, gray-whitish in color in the 1/3 part of approach pedicel and tan-redish in color in the residual part of the tumor with local hemorrhages and necrose and some small cysts. Tumor tissue for light microscopy was fixed in 10% neutrally buffered formalin and processed routinely in paraffin blocks. We cut 5-μm thick sections, then stained them with hematoxylin-eosin. Immunohistochemical analysis was done on formalin-fixed, paraffin-embedded tissue sections using a standard avidin-biotin complex technique. The primary antibodies used in this study are listed in Table 1. To evaluate the specificity of the antibodies, known positive and negative tissues were used as controls.Table 1: Primary antibodies used in the immunohistochemical studyHistologic examination of the esophagus specimen showed a malignant tumor made up of haphazardly arranged cell fascicles diffusely infiltrating the superficial muscle layer (Figure 1D). The tumor cells were arranged diffusely or in nests with hemorrhage and focal necrosis. A typical tumor cells lined the irregular spaces and single or small nests of cells grouped around a lumen containing red blood cells (Figure 1E). Higher magnification revealed that there were two types of epithelioid neoplastic cells: epithelioid cells with abundant eosinophilic cytoplasm and hyperchromatic or polymorphous nuclei, which contained prominent, sometimes multiple nucleoli; and pale cells with vesicular nuclei containing one or two prominent nucleoli. Mitoses were not prominent features. Precancerous lesions, carcinoma in situ and other cancer ingredients were not found in the tumor and the surrounding epithelium. The lymph nodes revealed no metastasis of tumor. Immunohistochemically, tumor cells for desmin, alpha-smooth muscle actin, S-100 protein, CD68, CD117/c-kit, cytokeratin 5/6, cytokeratin 8 and P63 were negative. Vimentin was strongly positive in the cytoplasm of the neoplastic cells. CD31 (Figure 1F), CD34, factor VIII-related antigen, and cytokeratin were all positive in the neoplastic cells. We also found this tumor can display weak expression for cytokeratins 7 and 18. Based on these findings, the final pathological diagnosis was EAS (grade II). The clinical diagnosis of EAS in the esophagus is difficult, duing to the nonspecific symptoms at presentation. Direct visualization with an endoscopy and biopsy of the suspected lesions is reliable for diagnosis. The pathological diagnosis may be a challenge, and immunohistological markers are needed to differentiate the tumor from poorly differentiated carcinomas. There are characteristic pathological findings macroscopically and microscopically. Grossly, the tumor is composed of whitish or greyish hemorrhagic tissue with areas of necrosis or calcification. It can sometimes have a lobulated pattern. Morphologically, EAS consists of solid and vasoformative areas. The solid areas contain a diffuse proliferation of large, polygonal, atypical, mitotically active, epithelioid cells containing abundant, granular, amphophilic, or eosinophilic cytoplasm. The vasoformative areas contain dilated, irregular, and anastomosing vascular channels lined by plump or spindle-shaped, atypical, endothelial cells with enlarged pleomorphic hypechromaticnuclei. EAS contains more areas exhibiting epithelioid differentiation than the classic vasoformative differentiation as seen in well differentiated angiosarcoma, more typical of cutaneous lesions.2 Because of the variegated histological features, the diagnosis may be difficult to reach based on pure morphology. EAS can mimic primary or metastatic poorly differentiated carcinoma, carcinosarcoma, malignant melanoma, lymphoma and many sarcomas with epithelioid features (particularly gastrointestinal stromal tumors). Therefore, immunohistochemical staining for endothelial and epithelial markers is often needed to establish a definite diagnosis. Immunohistochemically, vasoformative areas in the EAS can be positive for vimentin, ulex europaeus agglutinin-1 (UEA-1), factor VIII-related antigen, CD31, and CD34. In the epithelioid areas, EAS can display weak to focal strong expression for low-molecular-weight keratins such as cytokeratins 7, 8, and 18. Coupled with epithelioid morphology, this may create diagnostic confusion with poorly differentiated carcinoma; however, positive staining for vascular markers and proper morphological evaluation, specifically looking for vascular differentiation, help in distinguishing EAS from poorly differentiated carcinoma. Immunoperoxidase staining for S-100 and melanoma antigen recognized by T cells 1 (MART-1) is usually negative, and helps to exclude melanoma. An immunoperoxidase staining for c-kit (CD117) is usually negative, and similarly helps to exclude an epithelioid gastrointestinal stromal tumor. In the present case, the carcinomatous components were not observed. Immunohistochemistry played an important role in the diagnosis of angiosarcoma—particularly for poorly differentiated forms in which vascular channel formation is difficult to identify. Cytokeratin (CK) is present in about one third of soft-tissue angiosarcomas, particularly the epithelioid subtype, reflecting the fact that CK cannot be used as an absolute discriminant between angiosarcoma and carcinoma. The immuhohistochemistry of this tumor showed focal strong expressioin for CK and diffuse strong expression for vimentin. Angiosarcomas expressed (to a greater or lesser degree) the usual vascular antigens, including factor VIII-related antigen, CD31, and CD34. Therefore, we may diagnose the tumor as primary EAS of esophagus. Following a detailed and honest discussion with the patient, emphasizing the risk of local relapse and metastasis, he declined any adjuvant therapy. Two months later, he returned to the hospital because of heavy cramping chest pain. Investigation by CT scan revealed a mesenterial relapse and multiple lung metastases. Subsequently, there was rapid deterioration of his general condition. He finally developed fulminant respiratory failure and died one month later. No autopsy was performed. The prognosis of angiosarcoma is generally poor. Surgical resection currently offers the possible curative therapy for EAS, but the prognosis remains dismal, even with aggressive multimodal therapies, since metastatic disease is frequent and this tumour is resistant to currently available chemotherapeutic agents and radiotherapy. One surgical series of 44 patients with angiosarcoma at various sites reported a median patient survival of 20 months, and visceral involvement was associated with a far inferior prognosis when compared with other sites.3 The role of adjuvant therapy has yet to be determined; however, a subset analysis of a randomized, controlled trial of chemotherapy in sarcoma showed that doxorubicin-based regimens had a response rate of 25%.4 The role of adjuvant radiotherapy was also examined in 1 retrospective study of 67 patients and showed that adjuvant radiotherapy might improve disease-free survival.5 Further studies are certainly needed to establish the role of adjuvant radiation or chemotherapy in the treatment of angiosarcoma. Our patient died three months later after surgical resection without radiation or chemotherapy. In summary, EAS of esophagus is a rare, aggressive vascular malignancy characterized by sheets of epithelioid endothelial cells, which can mimic multiple other epithelioid malignancies. Yet, advances in pathological and immunohistochemical technology have enabled more accurate identification of the cellular origin of the specific tumor and have made the final diagnosis possible. Direct visualization with an endoscopy and biopsy of the suspected lesions can contribute to the diagnosis. Surgical resection, with adjuvant radiation or chemotherapy, is the best treatment modality. Acknowledgements: The authors thank TANG Yong-fei and HU Hong for providing technical assistance.